Form D · Pharmaceuticals
Entos Pharmaceuticals Inc.
Edmonton, A0 · CIK 0001812824
Offering snapshot reported May 26, 2020 · SEC filing
- Reported sold
- $100K Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 11, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2020 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-367695
Source: Form D, filed May 26, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Roy Duncan | Director |
| John Lewis | Executive |
| Arun Raturi | Executive |
| Andries Zijlstra | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2500 10220 103 Ave Nw
Edmonton, A0, T5J 0K4
Edmonton, A0, T5J 0K4